STAAR Surgical Reports Record Q1 Sales and Return to Profitability, Exceeding Expectations

summarizeSummary

STAAR Surgical announced a strong Q1 2026, achieving record net sales of $93.5 million and returning to profitability with a net income of $5.2 million, a significant turnaround from the prior year's losses.

check_boxKey Events

• Record Q1 Net Sales

  Net sales for Q1 2026 reached $93.5 million, a 119.6% increase compared to $42.6 million in Q1 2025, primarily driven by strong performance in China.

• Return to Profitability

  The company reported a net income of $5.2 million ($0.10 diluted EPS) for Q1 2026, a significant improvement from a net loss of $54.2 million ($-1.10 diluted EPS) in Q1 2025.

• Significant Gross Margin Improvement

  Gross profit margin increased to 73.6% in Q1 2026 from 65.8% in Q1 2025, reflecting cost reduction initiatives and improved production volumes.

• Reduced Restructuring Charges

  Restructuring, impairment, and related charges decreased substantially to $2.7 million in Q1 2026 from $22.7 million in Q1 2025.

auto_awesomeAnalysis

STAAR Surgical has reported a significant financial turnaround in Q1 2026, moving from a substantial net loss in the prior year to profitability. Net sales more than doubled year-over-year, driven by strong performance in China, and gross margins improved considerably. This marks a strong recovery from fiscal year 2025, which saw a significant drop in sales and a widened net loss. While cash and investments decreased in Q1 due to front-loaded payments, the company anticipates generating cash for the remainder of the year. This full quarterly report confirms and elaborates on the positive preliminary results announced earlier, reinforcing a positive shift in the company's operational and financial health.